Axogen director plans sale of 3,500 shares
Axogen, Inc. (AXGN) director Joseph A. Tyndall filed a Form 144 notice for a proposed sale of up to 3,500 shares of Axogen common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Axogen, Inc. (AXGN) director Joseph A. Tyndall filed a Form 144 notice for a proposed sale of up to 3,500 shares of Axogen common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $174,580 on NASDAQ as of September 2, 2026.
The 3,500 shares relate to Axogen common stock acquired on June 19, 2026 via Restricted Stock Units from the issuer. Form 144 is a notice of proposed sale under Rule 144 and does not itself confirm that the sale has occurred.
Key Figures
Key Terms
Rule 144 regulatory
Restricted Stock Units financial
person for whose account the securities are to be sold regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing for AXGN disclose about Joseph A. Tyndall?
What type of Axogen (AXGN) securities is Joseph A. Tyndall proposing to sell?
Which broker is listed in the AXGN Form 144 for Joseph A. Tyndall’s proposed sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.